L‐ornithine L‐aspartate vs placebo or no intervention
Non‐serious adverse events assessed using ICH‐GCP
It is very uncertain whether L‐ornithine L aspartate changes non‐serious adverse events assessed using ICH‐GCP compared with placebo or no intervention (very low certainty).
1 finding from 1 review
- L‐ornithine L‐aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis 2018 · Cochrane Headline outcomes onlyRR 1.15 [0.75, 1.77]14 studies · 1076 participantsVery low